Medexus Strikes Major Deal for Topical Terbinafine, Setting New Industry Standard

Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is thrilled to announce that it has acquired the exclusive Canadian rights to terbinafine hydrochloride nail lacquer, provided by Polichem – an Almirall group company focused on medical dermatology.

This product, which is set to be submitted to Health Canada for approval later this year, has had significant success in treating fungal nail infections in other markets. The Canadian fungicides market is estimated to be worth C$88 million annually, and Medexus is excited to bring this highly effective treatment to the country.

Medexus is thrilled to announce the addition of terbinafine hydrochloride to their product portfolio. This once-a-week treatment provides an excellent strategic fit with their market leading product Rupall®, and will give their primary care sales force an exciting new opportunity to expand their dermatology knowledge.

Following a Health Canada approval of terbinafine hydrochloride nail lacquer, their experienced team is ready to make this innovative product available to healthcare professionals and patients across Canada.

Medexus is excited to announce the acquisition of Terbinafine hydrochloride, a move that is expected to grow their Canadian revenues and further leverage their existing commercial infrastructure.

This acquisition is a prime example of Medexus’ ability to execute accretive transactions that make efficient use of their capital, with little to no effect on their near-term capital allocation strategy. Through this deal, Medexus aims to further engage their current leading product, Rupall®.

Medexus has partnered with Polichem to bring a new topical terbinafine nail lacquer to the Canadian market, with the aim of achieving Health Canada approval. To align the interests of both parties, Medexus has agreed to pay Polichem a low double-digit percentage of net sales in quarterly royalty payments, with an upfront payment and four sales-based milestone payments. This arrangement ensures that Medexus’s initial outlay is kept to a minimum and encourages successful product performance.

About Medexus

Medexus is revolutionizing the specialty pharmaceutical industry with its cutting-edge portfolio of treatments for hard-to-treat diseases. Through its North American commercial platform and its commitment to innovation, Medexus is providing life-changing solutions for those suffering from hematology, oncology, auto-immune diseases and allergy.

Leave a Comment